



533103

(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041179 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/US2003/034511
- (22) International Filing Date: 30 October 2003 (30.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/422,105 30 October 2002 (30.10.2002) US
- (71) Applicant (for all designated States except US): **THE UNITED STATES OF AMERICA** as represented by **THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH** [US/US]; Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BOCHAROV, Alexander, V.** [RU/US]; 11436 Mapleview Drive, Silver Spring, MD 20892 (US). **BARANOVA, Irina, N.**

[RU/US]; 3 Pooks Hill Rd 517, Bethesda, MD 20814 (US). **CSAKO, Gyorgy** [US/US]; P.O. Box 10576, Rockville, MD 20849 (US). **EGGERTON, Thomas, L.** [US/US]; 10900 Earlsate Lane, Rockville, MD 20852 (US). **PATTERSON, Amy, L.** [US/US]; 10900 Earlsate Lane, Rockville, MD 20852 (US). **REMALEY, Alan, T.** [US/US]; 4510 Traymore Street, Bethesda, MD 20814 (US). **VISHNYAKOVA, Tatyana, V.** [US/US]; 11436 Mapleview Drive, Silver Spring, MD 20892 (US).


(74) Agent: **AUERBACH, Jeffrey, I.**; Liniak, Berenato, & White, LLC, 6550 Rock Spring Drive, Suite 240, Bethesda, MD 20817 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: **SCAVENGER RECEPTOR B1 (CLA-1) TARGETING FOR THE TREATMENT OF INFECTION, SEPSIS AND INFLAMMATION**



(57) Abstract: This invention relates to methods and compositions for the treatment of sepsis, inflammation or infection. In particular, the invention concerns the use of molecule(s) that target SR-B1, which is also referred to as CLA-1 (SR-B1/CLA-1), to treat sepsis, bacterial and viral infections, and inflammatory diseases. SR-B1/CLA-1 ligands contributing to the pathogenesis of disease include LPS, LTA, viral envelope proteins, beta-amyloid, serum Amyloid A and/or heat shock proteins.

WO 2004/041179 A2



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*